The mechanism of clearance is the single most important piece of information a pre-clinical drug development program can obtain on its compounds. Knowing how a compound clears from the body gives insight into dosing regimen and into potential liabilities such as low bioavailability, drug-drug interactions, and accumulation.
Co-administration PK Screening
Mixtures of compounds dosed to a single animal. Reduce animal use, increase throughput, reduce cost.
Non-GLP
- Dose and draw
- Dose formulation
- Dose Limited Toxicity Screening
- Drug-drug interaction
- LC-MS/MS quantitative analysis
- PK parameter calculation
- Plasma, whole blood, urine, CSF, tissue homogenates
- Pre-clinical Species
- Protein and Antibody Therapeutics
- Routine Non-GLP
- Small molecule
Serial Micro-sampling in Mice
- Cancer research
- PK/PD
